On Monday, AbCellera Biologics Inc (NASDAQ: ABCL) opened higher 5.74% from the last session, before settling in for the closing price of $4.01. Price fluctuations for ABCL have ranged from $1.89 to $4.33 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -107.74%. Company’s average yearly earnings per share was noted -11.29% at the time writing. With a float of $223.95 million, this company’s outstanding shares have now reached $298.36 million.
The extent of productivity of a business whose workforce counts for 596 workers is very important to gauge. In terms of profitability, gross margin is -474.21%, operating margin of -1579.18%, and the pretax margin is -911.24%.
AbCellera Biologics Inc (ABCL) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of AbCellera Biologics Inc is 24.97%, while institutional ownership is 41.08%.
AbCellera Biologics Inc (ABCL) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -11.29% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 0.83% during the next five years compared to -107.74% drop over the previous five years of trading.
AbCellera Biologics Inc (NASDAQ: ABCL) Trading Performance Indicators
Check out the current performance indicators for AbCellera Biologics Inc (ABCL). In the past quarter, the stock posted a quick ratio of 10.15. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 54.74.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.57, a number that is poised to hit -0.14 in the next quarter and is forecasted to reach -0.50 in one year’s time.
Technical Analysis of AbCellera Biologics Inc (ABCL)
The latest stats from [AbCellera Biologics Inc, ABCL] show that its last 5-days average volume of 6.03 million was superior to 4.81 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 82.54%.
During the past 100 days, AbCellera Biologics Inc’s (ABCL) raw stochastic average was set at 93.63%, which indicates a significant increase from 85.71% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.31 in the past 14 days, which was higher than the 0.19 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.82, while its 200-day Moving Average is $2.77. Now, the first resistance to watch is $4.44. This is followed by the second major resistance level at $4.64. The third major resistance level sits at $4.87. If the price goes on to break the first support level at $4.00, it is likely to go to the next support level at $3.77. The third support level lies at $3.57 if the price breaches the second support level.
AbCellera Biologics Inc (NASDAQ: ABCL) Key Stats
There are currently 298,424K shares outstanding in the company with a market cap of 1.27 billion. Presently, the company’s annual sales total 28,830 K according to its annual income of -162,860 K. Last quarter, the company’s sales amounted to 4,240 K and its income totaled -45,620 K.
